Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy.
Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy.
复制标题
DOI：
10.3390/cells10030492
复制
发表时间：
2021-02-25
期刊：
影响因子：
6
通讯作者：
Chen WR
中科院分区：
文献类型：
--
作者：
Korbelik M;Hode T;Lam SSK;Chen WR
消融治疗已成为破坏癌组织的有效工具，但对于晚期和播散性肿瘤，其应用仍然主要是姑息性措施。然而，越来越清楚的是，这种限制可以通过使用肿瘤内免疫刺激剂来增强消融治疗诱导的潜在抗肿瘤免疫应答来纠正。新型免疫刺激药物IP-001是N-二氢半乳糖壳聚糖（GC）分子家族的一种特异性变体，当与不同形式的肿瘤消融结合时，已显示出对转移性肿瘤有效。它通过直接抑制细胞膜修复和消融损伤的肿瘤细胞的再循环，间接通过隔离消融释放的肿瘤抗原，以及募集和刺激抗原呈递细胞以诱导针对癌症的有效Th 1型T细胞应答，充当多功能免疫刺激剂。在这篇综述中，我们简要讨论了局部消融在癌症治疗中的当前应用以及GC与其他消融疗法相结合的效果，这是一种开创介入免疫肿瘤学（IIO）领域的治疗方法。
Ablation therapies have emerged as an effective tool for destroying cancerous tissue, but for advanced and disseminated tumors their application remains mainly a palliative measure. However, it is becoming increasingly clear that this limitation can be redressed by the use of intratumoral immune stimulating agents for amplifying potential antitumor immune responses that are induced by ablation therapies. A novel immune stimulating drug IP-001, a specific variant of the N-dihydrogalactochitosan (GC) family of molecules, has shown to be effective against metastatic tumors, when combined with different forms tumor ablation. It acts as a multi-function immune stimulant both by directly inhibiting cell membrane repair and recycling of ablation-damaged tumor cells, and indirectly by sequestering ablation-released tumor antigens, as well as recruiting and stimulating antigen presenting cells to induce a potent Th1 type T cell response against the cancer. In this review, we briefly discuss the current applications of local ablation for cancer treatment and the effects of GC in combination with other ablation therapies, a therapeutic approach that is pioneering the field of Interventional Immuno-Oncology (IIO).
登录
查看更多内容
影响因子：
2.4
作者：
Korbelik, Mladen
通讯作者：
Korbelik, Mladen
DOI：
10.3322/caac.20114
发表时间：
2011-07
期刊：
CA: a cancer journal for clinicians
影响因子：
--
作者：
Agostinis P;Berg K;Cengel KA;Foster TH;Girotti AW;Gollnick SO;Hahn SM;Hamblin MR;Juzeniene A;Kessel D;Korbelik M;Moan J;Mroz P;Nowis D;Piette J;Wilson BC;Golab J
通讯作者：
Golab J
DOI：
10.1053/j.tvir.2013.08.002
发表时间：
2013-12
影响因子：
1.7
作者：
Knavel EM;Brace CL
通讯作者：
Brace CL
影响因子：
3.3
作者：
Song S;Zhou F;Nordquist RE;Carubelli R;Liu H;Chen WR
通讯作者：
Chen WR
影响因子：
64.5
作者：
Gurcel, Laure;Abrami, Laurence;van der Goot, F. Gisou
通讯作者：
van der Goot, F. Gisou